Ozempic side effects on TikTok: separating fear from fact

What did @kevandkam.ladyshape actually say?

Honestly, the transcript here is nearly incomprehensible. The auto-generated captions appear to have failed entirely, producing fragments like "he is all about the father of a car" and references to someone named "Anthony" with no discernible context. What we can work with is the caption the creator wrote themselves, which is clearer and more substantive than anything in the spoken transcript.

The caption states that Ozempic causes weight loss by mimicking GLP-1, a hormone the body produces naturally. It lists three specific effects: slowing gastric emptying, reducing appetite, and making you feel "ra" (the caption was cut off, but almost certainly "rassasié," French for full or satiated). The creator frames this positively but teases a darker angle, asking "at what price?" This suggests the video was building toward a discussion of side effects or long-term consequences. Without a legible transcript, we can only fact-check what was written.

Does the science back this up?

The caption's core mechanism is accurate. Semaglutide does act on GLP-1 receptors, and the three listed effects are real and well-documented. Where things get more complicated is in what the caption implies but doesn't complete.

GLP-1 receptor agonists like semaglutide work by binding to GLP-1 receptors in the pancreas, gut, and brain. The result is a slowdown in gastric emptying, reduced glucagon secretion, and appetite suppression via hypothalamic signaling. This is not disputed. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean body weight reduction of 14.9% over 68 weeks in adults without diabetes, which is a genuinely significant result and the kind of outcome that drives viral content.

The framing that GLP-1 is "naturally produced by your body" is also accurate. GLP-1 is an incretin hormone released from intestinal L-cells after eating. Semaglutide is a synthetic analogue designed to resist enzymatic degradation, giving it a much longer half-life than endogenous GLP-1. That distinction matters clinically, even if it's fine to skip in a short video.

What did they get wrong (or right)?

The caption gets the mechanism right. Credit where it's due. The three listed effects (delayed gastric emptying, appetite reduction, satiety signaling) are accurate summaries of semaglutide's pharmacodynamic profile.

What's missing is context. The "at what price" framing is a dramatic hook, and it's not inherently wrong to frame it that way. But it creates an expectation that the tradeoffs will be explained seriously. Based on the caption alone, we can't verify whether the video actually did that.

The video appears to be in French, which raises an important regulatory point for any European viewer. Ozempic is approved in France for type 2 diabetes management. Wegovy (the higher-dose semaglutide formulation) received EMA approval for weight management in 2022. The distinction between these two formulations matters, and conflating "Ozempic" with general weight loss medication, as this video does in its caption, is a pattern that regulators in multiple countries have flagged as misleading. The French Agence nationale de sécurité du médicament (ANSM) has specifically warned about off-label Ozempic use for weight loss without diabetes diagnosis.

What should you actually know?

If this video was building toward a genuine discussion of GLP-1 side effects and long-term considerations, that is a conversation worth having. The science here is real, the side effect profile is real, and the nuance is genuinely useful to a public audience.

Common side effects include nausea, vomiting, diarrhea, and constipation, reported in 30 to 44 percent of participants in the STEP trials (Davies et al., 2021, Lancet). More serious but rarer concerns include pancreatitis risk, which remains under investigation, and a theoretical thyroid C-cell tumor risk identified in rodent studies, though human relevance is not established (Htike et al., 2017, Diabetes, Obesity and Metabolism).

The elephant in the room is weight regain. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who discontinued semaglutide regained about two-thirds of their lost weight within a year. This is the "price" most people discussing Ozempic either don't know or don't mention. It suggests the drug requires ongoing use to maintain its effects, which has real cost, access, and health-system implications that deserve serious discussion rather than a TikTok cliffhanger.

Anyone considering GLP-1 therapy should speak with a licensed prescriber who can assess their full medical history, not make decisions based on a viral video.